Terguride Receives FDA Orphan Drug Designation For The Treatment Of Pulmonary Arterial Hypertension
May 17th 2008Drug InformationHypertension
Ergonex Pharma announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to Terguride for the treatment of pulmonary arterial hypertension (PAH). Terguride is currently being evaluated for PAH in a pivotal Phase II trial in Europe.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
